Morgan Stanley raised the firm’s price target on Crispr Therapeutics (CRSP) to $33 from $32 and keeps an Underweight rating on the shares. The firm refreshed its Crispr estimates and reviewed incremental pipeline progress after partner Vertex Pharmaceuticals (VRTX) recently reported Q4 Casgevy sales.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio
- Crispr Therapeutics price target lowered to $67 from $69 at JPMorgan
- Crispr Therapeutics price target raised to $80 from $77 at Citi
- CRISPR Therapeutics: Casgevy Outperformance and 2026 Pipeline Catalysts Drive Raised $80 Target and Buy, High Risk Rating
- Crispr Therapeutics price target raised to $76 from $74 at Chardan